Buscopan and Rebif drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Buscopan (hyoscine butylbromide) and Rebif (interferon beta-1a). Common drug interactions include abdominal distension among females and blood glucose increased among males.

The phase IV clinical study analyzes what interactions people have when they take Buscopan and Rebif. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Buscopan?

Buscopan has active ingredients of hyoscine butylbromide. eHealthMe is studying from 4,828 Buscopan users. Check the latest studies of Buscopan.

What is Rebif?

Rebif has active ingredients of interferon beta-1a. It is often used in multiple sclerosis. eHealthMe is studying from 61,126 Rebif users. Check the latest studies of Rebif.

On Jul, 06, 2026

12 people who take Buscopan and Rebif together, and have interactions are studied.

What are the common drug interactions of Buscopan and Rebif, by gender? *:

female:

Abdominal distension
Fatigue (feeling of tiredness)
Pancreatitis (inflammation of pancreas)
Pain
Breast mass
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Gastrointestinal injury (injury to gastrointestinal tract)
Injection site erythema (redness at injection site)
Mass
Nausea (feeling of having an urge to vomit)

male:

Blood glucose increased
Dehydration (dryness resulting from the removal of water)
Productive cough
Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)
Diarrhoea
Mediastinum neoplasm (tumour in mediastinum)
Metastasis (spreadable cancer to other organ from origin)
Neoplasm malignant (cancer tumour)
Renal cancer (cancer of kidney)
Bladder cancer

What are the common drug interactions of Buscopan and Rebif, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Dyspnoea (difficult or laboured respiration)
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Influenza like illness
Pain
Perineal ulceration
Productive cough
Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)

50-59:

Abdominal distension
Breast mass
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Fatigue (feeling of tiredness)
Gastrointestinal injury (injury to gastrointestinal tract)
Injection site erythema (redness at injection site)
Mass
Nausea (feeling of having an urge to vomit)
Neoplasm malignant (cancer tumour)
Nephrolithiasis (calculi in the kidneys)

60+:

Blood glucose increased
Dehydration (dryness resulting from the removal of water)
Diarrhoea
Mediastinum neoplasm (tumour in mediastinum)
Metastasis (spreadable cancer to other organ from origin)
Neoplasm malignant (cancer tumour)
Renal cancer (cancer of kidney)
Bladder cancer
Pain

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 7 people, 58.33%
Pain: 2 people, 16.67%
Gallstones (stone formation by bile component): 2 people, 16.67%
Type 2 Diabetes: 1 person, 8.33%
Rectal Cancer Metastatic (cancer of rectum spreads to other): 1 person, 8.33%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 8.33%
Hot Flush (sudden feelings of heat): 1 person, 8.33%
Gastritis (inflammation of stomach): 1 person, 8.33%
Duodenitis (inflammation of the duodenum): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Buscopan and Rebif?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously